Published: Mar 05, 2021 By Mark Terry
Boston-based ABclonal Biotechnology
acquiredcontract research organization (CRO) Yurogen Biosystems, headquartered in nearby Worcester, Massachusetts. Yurogen focuses on producing antibodies and antibody-based products for its clients. Its technology platform is a monoclonal antibody discovery program using single-B-cell-based SMab. This technology platform allows for high-throughput development of high-affinity, high-specificity monoclonal antibodies. No financial details were disclosed.
Late in February, ABclonal, which calls itself a global life sciences tools and services provider,
completed a Series C financing round worth $92.9 million. It was led by Sequoia Capital China and healthcare-focused investors LYFE Capital. New and existing shareholders included Sigma Square Capital, Kinghall Ventures and Lucion Capital.